Due to GSK3B’s role in two separate pathways involving cell proliferation, as well as its direct effect on tau phosphorylation [43] and amyloid-beta production [44], developments have been made to target GSK3B for the treatment of Alzheimer’s disease. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.